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PURPOSE. To investigate whether Decorin, a matrikine that regulates extracellular matrix
(ECM) deposition, can reverse established trabecular meshwork (TM) fibrosis, lower IOP, and
reduce progressive retinal ganglion cell (RGC) death in a novel rodent model of TM fibrosis.
METHODS. Adult rats had intracameral (IC) injections of human recombinant (hr) TGF-b over 30
days (30d; to induce TM fibrosis, raise IOP, and initiate RGC death by 17d) or PBS (controls) and
visually evoked potentials (VEP) were measured at 30d to evaluate resultant visual pathway
dysfunction. In some animals TGF-b injections were stopped at 17d when TM fibrosis and IOP
were consistently raised and either hrDecorin or PBS IC injections were administered between
21d and 30d. Intraocular pressure was measured biweekly and eyes were processed for
immunohistochemical analysis of ECM deposition to assess TM fibrosis and levels of matrix
metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinases (TIMP) to assess
fibrolysis. The effect of hrDecorin treatment on RGC survival was also assessed.
RESULTS. Transforming growth factor–b injections caused sustained increases in ECM
deposition in the TM and raised IOP by 17d, responses that were associated with 42% RGC
loss and a significant decrease in VEP amplitude measured at 30d. Decorin treatment from 17d
reduced TGF-b–induced TM fibrosis, increased levels of MMP2 and MMP9 and lowered TIMP2
levels, and lowered IOP, preventing progressive RGC loss.
CONCLUSIONS. Human recombinant Decorin reversed established TM fibrosis and lowered IOP,
thereby rescuing RGC from progressive death. These data provide evidence for the candidacy
of hrDecorin as a treatment for open-angle glaucoma.
Keywords: TGF-b, Decorin, extracellular matrix, intraocular pressure, trabecular meshwork,
fibrolysis
Glaucoma describes a group of progressive optic neuropa-thies that have the potential to cause irreversible blindness
in which a main risk factor is raised IOP. In POAG, increases in
IOP occur when aqueous humour (AqH) outflow through the
trabecular meshwork (TM) is reduced, usually as a result of
abnormalities in TM cellularity,1–4 TM contraction,5,6 and
extracellular matrix (ECM) levels.4,7–9 The elastic-type fibers
in the TM are surrounded by a sheath of fine fibrils embedded
in an amorphous ECM made up of collagen IV, laminin, and
fibronectin. The presence of plaque material associated with
sheaths of the elastic-like fibers in the juxtacanalicular tissue
(JCT) within the TM (Sheath-derived [SD] plaques) are also a
pathological feature of POAG, with patients presenting with
significantly more, and thicker, SD-plaques in their TM
compared with eyes from age-matched controls.4,10–12 These
SD-plaques, however, are not thought to contribute to
increased outflow resistance since Lujten-Drecoll et al.,10
showed that eyes with psuedoexfoliation glaucoma had similar
levels of SD-plaque material when compared with healthy eyes,
but still had higher levels of IOP. Nevertheless, increased levels
of ECM are seen around TM sheaths and this deposition could
contribute to increased outflow resistance.13 These cellular and
ECM changes in the TM, together with altered TM cell
contractile abilities result in a dysfunctional TM and ultimately
loss of the tight control of AqH outflow.
The mechanisms that lead to TM dysfunction in POAG are
probably multifactorial, but pathologically high levels of TGF-b
within the AqH are thought to contribute.9,14–24 Some POAG
patients have elevated levels of TGF-b in their AqH compared
with AqH taken from age-matched patients with cataracts25–27
or other forms of glaucoma.28 A role for TGF-b in increasing
TM ECM deposition and IOP has been demonstrated by human
eye perfusion experiments29,30 and in rodent models of
glaucoma.16,20–22 Gene expression studies from cultured
human TM cells also support the assertion that both TGF-b1
and TGF-b2 isoforms induce the overexpression of ECM
proteins that may contribute to TM changes seen in
glaucoma.9,31,32 Additionally, TGF-b prevents the breakdown
of ECM by inhibiting the activation of matrix metalloprotei-
nases (MMP) through increasing levels of plasminogen
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activator inhibitor (PAI)-1 and tissue inhibitors of metal-
loproteinases (TIMP). Plasminogen activator inhibitor–1
inhibits the conversion of plasminogen to plasmin, which is
required for the plasmin-dependent activation of
MMP.14,18,33,34 The IOP-increasing effects of TGF-b have also
been attributed to the cytokine’s ability to reduce prolifera-
tion35 and induce apoptosis of TM cells,36 thereby reducing
the overall numbers of TM cells.19,24
Transforming growth factor–b also stimulates contraction
of TM cells through the RhoA-Rho kinase signaling pathway,31
with TM contractility significantly influencing IOP.37–39
Studies that have reduced or ablated RhoA-mediated TM
contraction using Rho/ROCK inhibitors, have led to new
classes of IOP lowering agents being considered to treat
glaucoma.37,40–42 However, it is unlikely that Rho/ROCK
inhibitors alone can address the chronic fibrotic pathology
that occurs in some patients with POAG, with their efficacy is
still under scrutiny. Ultimately, IOP elevations lead to
metabolic and biochemical changes in cells of the optic
nerve head and retina,43 which, together with the mechanical
axonal compression that affects both retrograde and antero-
grade axonal transport depriving RGC of neurotrophic
factors,44 culminates in RGC apoptosis and optic disc
cupping,45,46 features that are diagnostic of glaucoma.
The multifactorial etiology of POAG makes accurate
experimental modelling of the condition challenging. A major
impediment to testing antifibrotic/fibrolytic agents that
address TM fibrosis is the lack of reliable animal models that
mimic the fibrotic etiology of POAG. Although not replicating
the human condition perfectly, some current rodent models
are useful for evaluating therapeutics that reduce IOP and
prevent RGC death. For example, Junglas et al.16 used
adenovirus to overexpress the profibrotic connective tissue
growth factor (CTGF, a downstream mediator of TGF-b
effects) in order to demonstrate a link between CTGF and
TM fibrosis associated with increased IOP and RGC loss, but
they did not evaluate the efficacy of antifibrotic agents.
Ideally, fibrolytic treatments would be better assessed in a
chronic model of established TM fibrosis, whereby TM
fibrosis is sustained without the need for continued admin-
istration of the profibrogenic agent.
The matrikine Decorin is a small leucine-rich proteoglycan
that regulates cell proliferation, survival and differentiation by
antagonizing growth factors and/or their receptors, including
TGF-b,47–49 epidermal growth factor (EGF),50 vascular endothe-
lial growth factor (VEGF),51 insulin-like growth factor-I (IGF-I),52
as well as directly interfering with collagen fibrillogenesis.53
Decorin also increases MMP activity by increasing levels of tissue
plasminogen activator (tPA), enabling cleavage of plasminogen to
plasmin,54,55 a step that is required for plasmin-dependent
activation of MMP. Decorin also reduces PAI-1 and TIMP levels,
further facilitating MMP activation.54 Decorin’s fibrolytic actions
have been noted in many fibroproliferative pathologies, includ-
ing proliferative vitreoretinopathy,56 renal fibrosis,57 lung fibro-
sis,58 juvenile communicating hydrocephalus,47 and spinal cord
injury.54,55,59
Here, we investigated the fibrolytic properties of human
recombinant (hr) Decorin in the fibrosed TM using a rodent
model in which TM fibrosis is established by repeated
intracameral injections (IC) of TGF-b, with the fibrosis being
sustained upon withdrawal of the fibrogenic cytokine. We
predicted that (1) TGF-b–induced fibrosis of the TM would
permanently block AqH drainage, leading to increased IOP and
death of RGC with measurable effects on retinal function, and
(2) that treatment with hrDecorin would reduce established
TM fibrosis, lower IOP and indirectly protect RGC against
progressive death.
METHODS
Animals and Surgery
Eight- to 10-week-old, male, 175 to 200 g, Sprague Dawley rats
(Charles River, Kent, UK), housed with free access to food and
water, under a 12-hour dark/light cycle were used for all in
vitro and in vivo experiments. Surgery was performed at the
Biomedical Services Unit at the University of Birmingham
(Birmingham, UK) in accordance with the Home Office
guidelines set out in the 1986 Animal Act (UK) and the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. All ocular surgical procedures, electrophysiology,
and IOP measurements were completed under inhalational
anesthesia using 2% to 5% isofluorane/95% O2 (National Vet
Supplies, Stoke, UK) at a flow rate of 1.5L/min. Preoperative
0.1 mg/kg buprenorphine (National Vet Supplies) was admin-
istered and the postoperative welfare of all rats was monitored
closely.
Experimental Design
At 0 day (0d), one self-sealing incision was made through the
cornea into the anterior chamber using a 158 disposable blade
enabling repeat twice a week (biweekly) 3.5 lL IC injections
through the tunnel generated using self-made disposable sterile
glass micropipettes (Harvard Apparatus, Kent, UK) for 30d of
either PBS (control group PBS0-30d; Sigma, Poole, UK), active
hrTGF-b2 (treatment group TGF-b20-17d and treatment group
TGF-b20-30d; 5 ng/lL; Peprotech, London, UK), active hrTGF-b1
(5 ng/lL; Peprotech) between 0d and 17d then PBS between
21d and 30d (treatment group TGF-b10-17d/PBS21-30d), or active
hrTGF-b2 (5 ng/lL) between 0d and 17d then hrDecorin
between 21 and 30d (concentration derived from Ahmed et
al.54; 5 lg/lL; treatment group TGF-b20-17d/Decorin21-30d;
Catalent Pharma Solutions, Philadelphia, PA, USA).
Although both TGF-b1 and TGF-b2 were used to raise IOP in
this study, experiments with each isoform were analyzed
separately and induced similarly raised IOP, fibrosis, and RGC
death. Uninjured control eyes (intact) were also analyzed for
comparison to the PBS0-30d, TGF-b20-17d, and TGF-b20-30d
groups (Table 1). Intraocular pressure measurements were
taken biweekly in all treatment groups timed immediately
before the IC injections throughout the 30d experimental
period. Visually evoked potentials (VEP) in the PBS0-30d and
TGF-b20-30d groups were measured at 30d for model validation
to assess the functional consequences of RGC death and the
tissues from all groups were processed for immunohistochem-
istry (IHC) to assess levels of TM fibrosis and RGC survival.
IOP Measurements
Using an iCare Tonolab rebound tonometer (Icare, Helsinki,
Finland), IOP was recorded biweekly between 9 AM and 11 AM
for the duration of each experiment to avoid confounding the
readings with circadian variability. Immediately after induction
of anaesthesia with 5% Isoflurane, six rebound measurements
were taken with the tonometer from the central cornea on
each measurement occasion to give an overall average IOP
measurement (mm Hg) and all graphical data points represent
the mean 6 SEM of three readings (of 6 rebounds each) taken
sequentially to ensure accurate measurements (as previously
described60).
Visually Evoked Potentials
To ascertain if the RGC loss caused by the TGF-b–related IOP
rise led to functional retinal deficits, VEP measurements were
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compared between the PBS0-30d and TGF-b20-30d treatment
groups. Five days before VEP were recorded, the cranial skin
was resected and stainless steel screws (Bioanalytical Systems,
Inc., Kenilworth, UK) were implanted at 7-mm posterior to
the bregma, 3-mm lateral to the midline, at a depth of 0.5 mm
into the skull to connect the positive recording electrodes.
The reference (negative) screw electrode was inserted into
the skull in the midline, 3-mm anterior to bregma. The skin
was sutured around the screws. For VEP recordings at 30d,
rats were dark-adapted overnight and VEP recorded using an
Ocuscience HMsERG rodent ERG machine (Ocuscience,
Henderson, NV, USA) in a light-sealed room and prepared
under a dim red light. Rats were anaesthetized using 2%
isoflurane for the duration of recordings and readings were
taken at a controlled 378C temperature in a Faraday cage to
reduce electrical interference. A needle ground electrode was
placed in the midline dorsal subcutaneous tissue at the base
of the tail. Electrode impedance was maintained below 2 kX.
A mini-Ganzfeld stimulator was used with increasing stimulus
intensities of 300, 3000, and 25,000 mcd/s/m2, which were
averaged 100 times at each intensity with a recording
duration of 250 ms and an interstimulus interval of 1 second.
Visually evoked potentials from each eye were recorded
separately by uniocular occlusion allowing within subject
comparison of treatment/injury effects. Visually evoked
potentials amplitude and latency was measured in ERGView
(Ocuscience) by an observer blinded to the identity of the
treatment groups.
Tissue Preparation for Immunohistochemistry
Rats were killed by exposure to increasing concentrations of
CO2 and transcardially perfused with 100 mL of PBS to wash
out blood before further perfusion with 100 mL 4% parafor-
maldehyde (PFA) in PBS at pH 7.4. Dissected eyes for IHC were
post fixed by immersion in 4% PFA in PBS for 2 hours at 48C
before cryoprotection by immersion in increasing concentra-
tions of sucrose solutions (PBS with 10%, 20%, and 30%
sucrose; all from Sigma) for 24 hours each at 48C then
embedded in optimal cutting temperature (OCT) embedding
medium (Thermo Shandon, Runcorn, UK) in peel-away mould
containers (Agar Scientific, Essex, UK). Eyes immersed in OCT
were rapidly frozen in crushed dry ice before storage at808C
and later sectioned in the parasagittal plane through the optic
nerve head at228C using a Bright cryostat microtome (Bright,
Huntingdon, UK) at a thickness of 20 lm. Sections were
mounted on positively charged glass slides (Superfrost plus;
Fisher Scientific, Pittsburgh, PA, USA), left for 2 hours to dry at
378C and stored at 208C.
Retinal Cell Culture
Retinal cells were dissociated using a papain dissociation
system in accordance with the manufacturer’s protocol
(Worthington Biochem, Lakewood, NJ, USA) and 120 to 125
3 103 cells/well were cultured on sterile glass chamber slides
(BD Biosciences, Oxford, UK) precoated with 100 lg/mL
poly-D-lysine, followed by 20 lg/mL Laminin-I (both from
Sigma) in Neurobasal-A supplemented with B27-supplement,
L-glutamine, and penicillin/streptomycin (all from Invitrogen
Ltd., Paisley, UK), at 378C, in a humidified 5% CO2
atmosphere. After 24 hours in culture, supplemented Neuro-
basal-A (sNBA) was removed and retinal cells treated with
hrDecorin diluted to the test concentrations in fresh sNBA.
Wells were treated with 300 lL of either of sNBA (control) or
1, 10, 100, 1000 lg/mL concentrations of hrDecorin in sNBA,
and grown for a further 3d, at 378C, in a humidified 5% CO2
atmosphere.
Immunocytochemistry
Retinal cultures were fixed in 4% PFA in PBS at room
temperature (RT) for 10 minutes, washed 33 5 minutes with
0.1% Triton X-100 (Sigma) in PBS and blocked in 0.1% Triton
X-100 with 10% normal goat serum (Serotec, Oxfordshire,
UK) and 3% bovine serum albumin (BSA; Sigma) in PBS for 30
minutes at RT. Cultures were incubated in mouse anti–bIII-
tubulin antibody (1/500; Sigma) for 1 hour at RT. Cultures
were then washed 335 minutes in PBS and incubated in goat
anti-mouse IgG Alexa Fluor 488 secondary antibody (1/400;
Invitrogen) for 1 hour. After washing in PBS, slides were
mounted using Vectamount containing 4 0,6-diamidino-2-phe-
nylindole (DAPI; Vector Labs, Peterborough, UK) and viewed
using a Zeiss Axioplan2 epi-fluorescent microscope equipped
with an AxioCam HRc camera and Axiovision software (all
from Carl Zeiss, Hertfordshire, UK). Control tissue sections
incubated with secondary antibody alone were all negatively
stained (not shown).
TABLE 1. Experimental Design for IC Injections
In vivo experimental groups detailing the biweekly IC injection regimes.
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Immunohistochemistry
Frozen sections were left to thaw for 30 minutes before 33 5
minutes washing in PBS followed by a 20 minutes permeabi-
lization with 0.1% Triton X-100 (Sigma). Nonspecific antibody
binding sites in tissue sections were blocked for 30 minutes in
0.5% BSA, 0.3% Tween-20 (all from Sigma), and 15% normal
goat serum (Vector Laboratories) in PBS before incubating
overnight in primary antibody (Table 2) followed by washing 3
3 5 minutes in PBS and incubating for 1 hour at RT with
secondary antibody (Table 2). Sections were then washed 335
minutes in PBS and mounted in Vectorshield mounting
medium containing DAPI (Vector Laboratories). Control tissue
sections incubated with secondary antibody alone were all
negatively stained (not shown).
Quantification of Immunohistochemistry
After immunofluorescence staining, sections were viewed on a
Zeiss Axioplan 2 epi-fluorescent microscope (Carl Zeiss Ltd.)
and images captured using the same exposure times (Laminin,
fibronectin, and Decorin at 250 ms; MMP2 at 1.2 seconds,
MMP9 and TIMP2 at 1 second) for each antibody using a Zeiss
AxioCam HRc. Immunohistochemistry staining was quantified
according to the methods previously described.47 Briefly, the
region of interest used for quantitation of TM fibrosis was
defined by a quadrant of the same prescribed size for all eyes/
treatments within the TM. Extracellular matrix deposition was
quantified within this defined quadrant of the TM and the
percentage of immunofluorescent pixels above a standardized
background threshold was calculated using ImageJ software
(http://imagej.nih.gov/ij/; provided in the public domain by
the National Institutes of Health, Bethesda, MD, USA). For each
antibody, the threshold level of brightness in the area of the TM
was set using intact untreated eye sections to define the
reference level for test group analysis of pixel intensity. Images
were assigned randomized numbers to ensure blinding of
treatment groups during quantification by the assessor.
For quantification of RGC in retinal sections, Brn3aþ/DAPIþ
RGC were counted in 20-lm thick parasagittal sections of
retina from a 250-lm linear portion from the ganglion cell layer
(GCL) either side of the optic nerve (as previously pub-
lished62). Eight retinal sections from each eye in the control
and treatment groups (Table 1) were quantified. Images were
assigned randomized numbers to ensure blinding of treatment
groups during quantification by the assessor.
For quantification of macrophages, ED1þ/DAPIþ cells were
counted in 20-lm thick parasagittal sections of the eye. ED1þ/
DAPIþ cell counts were performed in 500 3 400 lm (320)
Axiovision images of the anterior chamber angle (as ED1þ cells
were only observed in the angle) of n ¼ 3 eyes from intact,
PBS0-30d– and TGF-b20-30d–treatment groups. Images were
assigned randomized numbers to ensure blinding of treatment
groups during quantification by the assessor.
Quantification of RGC in Retinal Cultures
bIII-tubulinþ RGC were counted using Image Pro 6.2 at 320
magnification in nine equal areas of each well from four
random fields of view, totalling 36 images/well. The mean
number of bIII-tubulinþ RGC/mm2 6 SEM was calculated for
each image captured within a 0.2475 mm2 area of each culture
well (36 images per well represented 363 0.2475¼ 8.91 mm2)
using previously published methods.63,64 Retinal ganglion cell
counts were performed by an assessor who was blinded to the
identity of the treatment groups.
Statistics
All statistical analyses were performed using SPSS 20 (IBM,
Chicago, IL, USA). Normal distribution tests were carried out to
determine the most appropriate statistical analysis to compare
treatments. Statistical significance was determined at P less
than 0.05. Intraocular pressure data were analyzed for
significant differences using the within-subjects repeated
measured design or generalized estimated equations. Trabec-
ular meshwork fibrosis, inflammation, RGC survival, and VEP
data were tested for significant differences using Student’s t-
test or one-way ANOVA for greater than two group compar-
isons 6SEM and are given in the text or displayed graphically
as mean 6 SEM. For in vitro RGC survival, between group
differences in RGC 6 SEM counts were analyzed for
significance using ANOVA.
RESULTS
Inflammation Induced by IC Injection
The inflammation induced by repeated IC injection was
assessed by counting macrophages/unit area (ED1þ cells) in
the angle of eyes from the intact, PBS0-30d and TGF-b20-30d
groups. The morphology of the eyes remained macroscopically
unchanged between intact and treatment groups and there was
no evidence of cataracts, hemorrhage, or inflammation in any
of the eyes. There was an increase in ED1þ/DAPIþ cells within
the iridocorneal angle of eyes that received IC injections of
PBS0-30d and TGF-b20-30d (9 6 3 and 12 6 3 cells, respectively)
compared with intact eyes (3 6 3 cells; P < 0.001). However,
there were no significant differences in ED1þ/DAPIþ cell
TABLE 2. Antibodies Used in Immunohistochemistry
Antigen Dilution Supplier Catalogue No. To Identify
Laminin47 1:200 Sigma (Poole, UK) L9393 TM fibrosis
ED147 1:400 Serotec (Kidlington, UK) MCA341GA Macrophage
Fibronectin47 1:200 Sigma F3648 TM fibrosis
Human Decorin47 1:400 Abcam (Cambridge, UK) Ab54728 TM fibrosis
MMP261 1:100 Abcam Ab37150 Pro- and active MMP2 levels
MMP961 1:100 Santa Cruz (Santa Cruz, CA) SC-10737 Pro- and active MMP9 levels
TIMP261 1:100 Santa Cruz SC-5539 Pro- and active TIMP2 levels
Brn3a62 1:100 Santa Cruz SC-31984 RGC
Donkey anti-mouse IgG, Alexa Fluor 488 1:400 Molecular Probes (Paisley, UK) A-21202 Secondary IgG for mouse primary antibodies
Goat anti-mouse IgG Alexa Fluor 594 1:500 Molecular Probes A-11032 Secondary IgG for mouse primary antibodies
Donkey anti-goat IgG, Alexa Fluor 594 1:400 Molecular Probes A-11058 Secondary IgG for goat primary antibodies
Donkey anti-rabbit IgG, Alexa Fluor 594 1:400 Molecular Probes A-21207 Secondary IgG for rabbit primary antibodies
Donkey anti-rabbit IgG, Alexa Fluor 488 1:400 Molecular Probes A-21206 Secondary IgG for rabbit primary antibodies
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counts between the PBS0-30d and TGF-b20-30d groups (Fig. 1).
The increase in macrophage numbers noted demonstrates that
the IC injection caused an inflammatory response within the
angle by 30d, with no added effect of TGF-b2.
IC Injections of TGF-b Raises IOP
We evaluated whether IC injection of TGF-b led to the
development of TM fibrosis and raised IOP, in order to confirm
that our model replicated some of the pathological features of
FIGURE 1. Inflammatory response generated from IC injections. The panels show parasagittal eye sections illustrating macrophages in the
iridocorneal angle. (A) ED1 (red) and DAPI (blue) immunostaining in intact, PBS0-30d-, and TGF-b20-30d–treated groups. (B) The number of ED1þ/
DAPIþ cells in the iridocorneal angle. Intact eyes had significantly less ED1þ/DAPIþ cells compared with PBS0-30d- and TGF-b20-30d–injected eyes (***P
< 0.001). Scale bar: 100 lm.
FIGURE 2. Intraocular pressure measurements after biweekly IC TGF-b injections. Tonometer IOP measurements show a significant elevation in IOP
by 7d that was sustained through 30d in the eyes of the TGF-b20-30d group compared with the PBS0-30d group (*P < 0.05 ***P < 0.001). The normal
IOP range from intact eyes is indicated by the shaded area.
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human POAG. Compared with the PBS0-30d group, IOP
increased in the TGF-b20-30d group, although statistical
significance was not achieved until 7d, before which the IOP
remained within the normal range of 10.4 6 0.3 to 12.4 6 0.7
mm Hg (Fig. 2). From 7d until 30d, IOP increased and was
maintained at a significantly higher level of 14 6 0.3 mm Hg at
30d in the TGF-b20-30d–treated group (P < 0.05 at 7–14d; P <
0.001 between 14–30d)when comparedwith IOP in the PBS0-30d
group, which remained within the normal range of 10.56 0.4 to
11.7 6 0.3 mm Hg throughout. The sustained increase in IOP
demonstrates that TGF-b is a suitable agent to induce increased
IOP by IC injection in rats.
IC Injections of TGF-b Induces TM Fibrosis
In the control Intact and PBS0-30d groups, the ciliary body, iris,
and vascular basement membranes were all lamininþ, partic-
ularly around the outer wall of Schlemm’s Canal, although
lamininþ immunoreactivity was thin along the inner wall (not
shown). Thin linear strands of lamininþ tissue were also
present within the TM of the intact and PBS0-30d control
groups, while increased lamininþ immunoreactivity was
observed in and about the TM of the TGF-b20-17d and TGF-
b20-30d groups compared with levels in the PBS0-30d control
group (P < 0.001; Figs. 3A, 3B, 3C). There were no significant
differences in laminin levels between the TGF-b20-17d and TGF-
b20-30d groups. In both TGF-b groups, laminin immunoreactiv-
ity was also particularly prominent in the inner wall of
Schlemm’s canal.
At 17d and 30d, the TM was also densely packed with
fibronectin deposits in the TGF-b20-30d group, unlike the Intact
and PBS0-30d control groups where little or no fibronectin
deposits were observed (Fig. 3D), so that fibronectin levels
around the TM were significantly higher in the TGF-b20-17d and
TGF-b20-30d groups compared with the TM of the PBS0-30d
control group (P < 0.001; Fig. 3E). There were no significant
differences in fibronectin levels between the TGF-b20-17d and
TGF-b20-30d groups. These findings demonstrate that IC
injections of TGF-b caused excess ECM deposition within and
around the TM and Schlemm’s Canal and that the ECM
deposition occurred by 17d and was maintained at similar
levels through to 30d.
TGF-b Induced Fibrosis and Raised IOP Is
Associated With RGC Death and Perturbed Retinal
Function
Compared with the intact control group (Fig. 4A), Brn3aþ RGC
counts from the PBS0-30d- (Fig. 4B), and TGF-b20-17d– (Fig. 4C)
treated groups were not significantly different. However, when
FIGURE 3. Trabecular meshwork fibrosis in the iridocorneal angle. The
panels show parasagittal eye sections illustrating: (A) the region of
interest example of quantified areas in the TM (white boxes) and
laminin (red) DAPI (blue) for illustrative purposes; (B) laminin (red)
immunostaining in intact and PBS0-30d control groups and also in TGF-
b20-17d– and TGF-b20-30d–treated groups. (C) Quantification of the
percentage lamininþ pixels in a defined area within the TM
demonstrating significantly increased laminin immunoreactivity in the
TGF-b20-17d– and TGF-b20-30d–treated groups (P < 0.001) compared
with intact and PBS0-30d controls. (D) Fibronectin (green) immuno-
staining in the TM of intact and PBS0-30d control groups and also in
TGF-b20-17d– and TGF-b20-30d–treated groups. (E) Quantification of the
percentage fibronectinþ pixels in a defined area within the TM
demonstrating significantly increased fibronectin immunoreactivity in
the TGF-b20-17d– and TGF-b20-30d–treated groups (***P < 0.001)
compared with intact and PBS0-30d controls. Scale bar: 100 lm; SC,
Schlemm’s Canal.
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compared with the counts in the intact (43 6 2 RGC/mm) and
the PBS0-30d (49 6 2 RGC/mm) control group retinae, RGC
counts from the TGF-b0-30d–treated group (Fig. 4D) were
lowered (28 6 3 RGC/mm, P < 0.001), indicating statistically
significant RGC death (Fig. 4E). The Brn3aþ RGC counts in the
TGF-b20-17d–treated group were higher than those in the TGF-
b20-30d–treated group and not significantly different from RGC
numbers in control intact and PBS0-30d groups, suggesting that
most of the RGC loss occurred between 17d and 30d.
The RGC loss was associated with a significant decrease in
the P1/N2 VEP amplitude in the TGF-b20-30d–treated group
when compared with the control PBS0-30d group (P < 0.01;
Figs. 5A, B), but there was no change in P1/N2 latency (P >
0.05).
hrDecorin Attenuates TGF-b–Induced IOP
Elevation
We next investigated whether IC hrDecorin delivered over the
21d to 30d period attenuated the IOP elevation and TM fibrosis
established by IC TGF-b injections delivered between 0d and
17d, as well as the effects of hrDecorin on RGC survival.
Having caused a sustained elevation in IOP through repeated
IC TGF-b2 injections over 17d, administration of hrDecorin
between 21d and 30d significantly and contemporaneously
decreased IOP to control levels (P < 0.001; Fig. 6).
Accordingly, the IOP in the TGF-b20-17d/Decorin21-30d group
was still at 15 6 2 mm Hg at 21d, indistinguishable from IOP in
the TGF-b10-17d/PBS21-30d group at 14 6 2 mm Hg. However,
by 30d the IOP in the TGF-b20-17d/Decorin21-30d group had
significantly lowered to 10 6 0.6 mm Hg compared with an
IOP of 16 6 1 mm Hg in the TGF-b10-17d/PBS21-30d group at
30d. Hence, hrDecorin delivered between 21d and 30d
reduced IOP to levels similar to values recorded in the Intact
and the PBS0-30d control groups by 30d.
hrDecorin Causes the Dissolution of Established
TM Fibrosis
In the TGF-b20-17d/Decorin21-30d group, laminin and fibronectin
deposits were significantly reduced at 30d (P < 0.05; Fig. 7A–D)
throughout the TM compared with those in the TGF-b10-17d/
PBS21-30d and TGF-b20-17d control groups (Fig. 7). Laminin
immunoreactivity in the TGF-b10-17d/PBS21-30d control group
was observed most prominently throughout the inner wall of
Schlemm’s Canal, while fibronectin was deposited throughout
the TM but was most prominent within the JCT region. However,
the TGF-b20-17d/Decorin21-30d regime significantly (P < 0.001)
reduced these deposits, giving a similar pattern of laminin and
fibronectin staining to that observed in the PBS0-30d and intact
control groups. The decrease in laminin and fibronectin deposits
in the TM shown by immunohistochemistry, together with the
lowered IOP, suggests that injections of hrDecorin over the
period of 21d to 30d caused the dissolution of established fibrosis
induced by IC TGF-b injections over the 0d to 17d period.
hrDecorin Induces Fibrolysis of TM ECM by
Increasing the MMP/TIMP Ratio
We next investigated whether hrDecorin modulated lysis of
TGF-b-induced TM fibrosis through modulation of the MMP
axis. Immunostaining was undertaken to localize hrDecorin in
the TM at 30d (Figs. 8A, 8E). In the PBS0-30d and TGF-b10-17d/
PBS21-30d control groups, little hrDecorin
þ immunoreactivity
was observed. By contrast, levels of hrDecorin in the TGF-b20-17d/
Decorin21-30d group were significantly higher within the TM
compared with the PBS0-30d and TGF-b10-17d/PBS21-30d control
groups (P < 0.001), reflecting the local accumulation of injected
hrDecorin in the TGF-b20-17d/Decorin21-30d group (Fig. 8E). The
constitutive levels of total MMP2 staining in the TM seen in the
control PBS0-30d group (Figs. 8B, E) and the intact group (not
shown) were suppressed in the TGF-b10-17d/PBS21-30d group, an
FIGURE 4. BRN3aþ RGC counts in the GCL. The panels show: (A)
Brn3aþ(red)/DAPIþ(blue) RGC in parasagittal retinal sections from the
intact control group. (B) Brn3aþ/DAPIþ RGC in the PBS0-30d control
group. (C) Brn3aþ/DAPIþ RGC in the TGF-b20-17d–treated group. (D)
Brn3aþ/DAPIþ RGC in TGF-b20-30d–treated group. (E) Quantification of
Brn3aþ/DAPIþ RGC survival in the intact and PBS0-30d control groups
and also in the TGF-b20-17d– and TGF-b20-30d–treated groups. IC TGF-
b20-30d was associated with significantly higher levels of RGC death
when compared with intact, PBS0-30d and TGF-b20-17d groups (***P <
0.001). Scale bar: 100 lm.
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effect that was neutralized by TGF-b20-17d/Decorin21-30d treat-
ment, increasing levels of MMP2 to those seen in the PBS0-30d
group (Figs. 8B, 8E). Similarly, the TMof the TGF-b10-17d/PBS21-30d
group had significantly lower levels of immunoreactive MMP9
than did the PBS0-30d and TGF-b20-17d/Decorin21-30d groups (Figs.
8C, 8E). Conversely, TIMP2 immunoreactivity was similar in both
PBS0-30d and TGF-b10-17d/PBS21-30d groups, but was significantly
lowered in the TGF-b20-17d/Decorin21-30d group (Figs. 8D, 8E).
Quantitation of the immunoreactivity confirmed these changes in
the TGF-b20-17d/Decorin21-30d group, so that there was a
significant (P < 0.05) increase of the MMP2/9:TIMP2 ratio in
the TM, favoring MMP activation (Table 3). Thus, TGF-b
suppressed MMP2/9 activation in the TM favoring fibrogenesis
and hrDecorin reversed this effect, suggesting a mechanism for
hrDecorin-mediated lysis of established TM fibrosis.
hrDecorin Treatment Is Indirectly RGC
Neuroprotective
In the TGF-b20-17d/Decorin21-30d group there were significantly
higher numbers of surviving RGC at 30d compared with the
TGF-b10-17d/PBS21-30d control group, with 41 6 4 RGC/mm
and 27 6 2 RGC/mm, respectively (P < 0.001; Figs. 9A–C),
demonstrating that IC hrDecorin attenuated RGC loss between
21d and 30d as observed in Figure 4D. To assess whether this
reflected a direct or indirect effect of hrDecorin on RGC, the
neuroprotective effects were tested in vitro. Treatment of
FIGURE 5. Functional assessment of the visual pathway using flash VEP. (A) Representative VEP recordings at flash intensity of 3000 mcd.s/m2
showing a decrease in wave amplitude in the TGF-b20-30d–treated group compared to the PBS0-30d control group. (B) Average VEP amplitude at P1/
N2 in the PBS0-30d and the TGF-b20-30d groups. There was a significant reduction in wave amplitude at P1/N2 in the TGF-b20-30d–treated group
compared with the PBS0-30d control group (n¼ 8 eyes/group **P < 0.01).
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retinal cell cultures with increasing concentrations of exoge-
nous hrDecorin did not significantly change the b-III tubulinþ
RGC frequency in any of the Decorin treatment groups (1, 10,
100, or 1000 lg/mL) compared with controls (P ¼ 0.849).
Thus, there was no direct neuroprotective effect of hrDecorin
on RGC apparent in vitro (Fig. 9D), implying that the RGC
protection observed in vivo was indirect and a consequence of
hrDecorin-mediated IOP reduction.
DISCUSSION
Repeated IC injection of TGF-b in adult rats induced TM
fibrosis and elevated IOP leading to RGC death and retinal
dysfunction, shown by IHC, IOP measurements, RGC counts,
and VEP recordings. We have demonstrated that IC hrDecorin
treatment decreased fibrosis established by IC TGF-b within
the TM (an effect accompanied by increased local levels of
MMP2 and MMP9 and reduced levels of TIMP2 implying
increased fibrolysis), lowered the raised IOP and, by lowering
IOP, indirectly protected the retina from progressive RGC
death.
Consistent with other fibrotic models of raised IOP,20,22 our
rodent model of IC TGF-b injections generated a sustained and
significant increase in IOP by 14d compared with controls. The
baseline level of IOP (before any treatment) reported in the rat
by Robertson et al.20 is similar to that seen in our study.
However, overexpression of TGF-b by gene transfer in the
Robertson et al.20 study led to sustained IOP elevations of
greater than 20 mm Hg at 14d, higher than our recordings of
greater than 14 mm Hg at 14d, probably explained by the
constant production of TGF-b through gene transcription
compared with our discontinuous bolus regime of biweekly IC
injections. Nevertheless, our protocol did cause TM fibrosis
accompanied by a sustained rise in IOP, significant RGC loss
and retinal dysfunction. An advantage of our model is that TGF-
b treatment could be stopped at 17d to reveal that by this time
point the IOP was elevated, probably through established TM
fibrosis and perturbed AqH drainage. It could be argued that
the cessation of TGF-b treatment once fibrosis was established
in our model would, over longer time periods, lead to a natural
resolution of fibrosis and IOP (due to continued ECM turnover
in the TM). However, such resolution was not apparent in the
TGF-b10-17d/PBS21-30d treatment group.
We found that raised levels of TGF-b in the AqH induced a
robust amount of TM fibrosis. Trabecular meshwork cells
contain a high density of TGF-b receptors, making the TM
particularly sensitive to raised levels of AqH TGF-b1/TGF-
b2.15,27,31 Binding to a common receptor, TGF-b1/TGF-b2
activates a common intracellular Smad signaling pathway in TM
cells, increasing synthesis and local accumulation of ECM
proteins, as well as suppressing local ECM protease activity by
downregulating MMP,14 resulting in increased TM fibrosis and
enhanced resistance to AqH outflow. In our study, TGF-b–
induced TM fibrosis led to an increase in IOP by 17d that was
sustained through to 30d and was associated with 42% RGC
death at 30d. The functional VEP deficits seen at 30d validate
the retinal effects of our TM fibrotic model and are consistent
with VEP deficits seen in other experimental models of raised
IOP.65
Another important factor to consider in our model was the
inflammation caused by repeated IC injections. In our study
inflammation was measured by counting the number of ED1þ
macrophages found in the iridocorneal angle. Our results
showed that IC injections increased the number of macro-
phages in the angle compared with numbers in the intact
control eyes, but there were no differences in macrophage
numbers between the PBS0-30d and TGF-b20-30d groups. In light
of this, we concluded that any measured differences seen
between the two treatments were a consequence of differenc-
es in the effects of the delivered agents and were not due to
inflammatory effects related to the surgical procedure.
Decorin is naturally found as part of the TM ECM and its
presence here is essential to maintain the integrity of the AqH
outflow system under normal physiology. However, Decorin
also regulates many signalling pathways associated with TM
pathologies (e.g., by sequestering TGF-b and inhibiting its
associated signalling through Smad2 and Smad3 path-
ways),47,48 thereby preventing TM cells from becoming
FIGURE 6. Intraocular pressure measurements after IC injection of TGF-b20-17d/Decorin21-30d and TGF-b10-17d/PBS21-30d. The graph shows that the
sustained elevation in IOP induced by 17d of TGF-b IC injections was reversed by subsequent IC Decorin injections in the TGF-b20-17d/Decorin21-30d
group. Intraocular pressure in the TGF-b10-17d/PBS21-30d control group continued to rise beyond 17d when IC TGF-b injections were stopped and
replaced by PBS injections (***P < 0.001).
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fibroblast-like and depositing ECM. In addition, Decorin
sequesters other growth factors, including IGF-1,52 EGF,50
platelet-derived growth factor (PDGF),66 and VEGF,51 and
interferes with related receptors, as well as directly binding
to collagen to alter fibrillogenesis.53 The direct dissolution of
ECM by Decorin-induced MMPs, is also well documented.55,67
In addition to the Decorin-induced reduction of laminin and
fibronectin in the scarred TM, we demonstrated that Decorin
altered MMP/TIMP ratios in the TM that were favorable to TM
fibrolysis, which probably accounted for the dissolution of
established ECM protein deposits in and around the TM.
Multiple rodent central nervous system injury models have also
demonstrated similar antifibrogenic and fibrolytic actions of
Decorin in pathological scenarios of both acute and chronic
scarring.55,59,67
Others have shown that Decorin lowers IOP through
attenuation of conjunctival scarring in a rabbit model of
glaucoma filtration surgery,68 supporting our observation of
reduced IOP through antifibrotic effects of Decorin in the TM.
Sequential staging of the injections of TGF-b and Decorin
injections in the TGF-b0-17d/Decorin21-30d group exclude the
possibility of direct antagonism of exogenously delivered TGF-
b by Decorin, implying that the IOP reduction observed with
Decorin treatment was not related to direct antagonism of TGF-
b, but was a consequence of lysis of the established TM
fibrosis, probably by activation of locally produced fibrolytic
MMP and coincident inactivation of TIMP.
It is becoming widely accepted that dysfunctional ECM
remodelling leads to TM fibrosis in open angle glaucoma
(Maatta M, et al. IOVS 2002;43:ARVO E-Abstract 2458 and Refs.
69–71). We believe that the rise in IOP seen by 14d and
sustained through 30d in this study was due to the
development of TM scarring over this period, a contention
supported by the fibrosis data shown in both the TGF-b0-17d
and TGF-b0-17d/PBS21-30d groups. The rebalancing of MMP:TIMP
ratios toward fibrolytic activity mediated by Decorin54
treatment is mirrored by the pathology of POAG in which
MMPs, released from the TM cells, regulate AqH outflow
resistance by modulating ECM turnover in the TM.72,73 Studies
that involve stretching of TM cells by eye perfusion have
shown that increased IOP leads to upregulated levels of MMP2
and downregulated TIMP2 levels, thus favoring ECM degrada-
tion with consequent lowering of IOP.72 In the present study,
Decorin treatment similarly reversed established TM fibrosis,
making Decorin a candidate drug to reverse the pathology of
ocular hypertension and various forms of open-angle glauco-
ma.
Although Decorin treatment lowered IOP and increased
RGC survival compared with controls in vivo, our in vitro study
demonstrated that Decorin was not directly RGC neuropro-
tective. Seidler et al.74 reported an antiapoptotic effect of
Decorin in cultured fibroblasts by prevention of DNA
fragmentation. Others have also shown that Decorin promotes
survival of endothelial and epithelial cells49,75 but conversely,
there is a body of literature from cancer cell studies that
convincingly demonstrates the ability of Decorin to induce
apoptosis,76–78 so cell context is seemingly important to
Decorin actions. Given that, in our primary retinal cultures
Decorin did not demonstrate any significant RGC survival, we
infer that the Decorin-related neuroprotection observed in vivo
was probably indirect and attributable to the IOP-lowering
effects that reflected restoration of normal AqH outflow as a
FIGURE 7. Fibrosis in the TM with and without Decorin treatment after
sustained IOP elevation induced by IC TGF-b injections. The panels
show parasagittal eye sections illustrating areas of fibrosis in the angle
containing the TM and Schlemm’s canal revealed by (A) immunostain-
ing of laminin (red) and (B) quantitation of the laminin immunostain-
ing within a defined region of the TM. (C) Immunostaining for
fibronectin (green) and (D) quantitation of the fibronectin immuno-
staining within a defined region of the TM. The excess deposition of
laminin and fibronectin about the TM, induced by IC TGF-b10-17d/
PBS21-30d treatment, was significantly reversed by Decorin treatment in
the TGF-b20-17d/Decorin21-30d–treated group (***P < 0.001). Scale bar:
100 lm.
TABLE 3. MMP:TIMP Ratio After PBS0-30d, TGF-b10-17d/PBS21-30d, and
TGF-b20-17d/Decorin21-30d Treatments
PBS 0-30d
TGF-b0-17d/
PBS21-30d
TGF-b0-17d/
Decorin21-30d
MMP2:TIMP2 1.33 0.81 4.66
MMP9:TIMP2 1.33 0.85 6.16
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FIGURE 8. Decorin and protease levels in the TM. Panels show representative images of immunoreactive (green). (A) Decorin in the angle, (B) total
MMP2, (C) total MMP9, and (D) total TIMP2 within the TM of the PBS0-30d and TGF-b10-17d/PBS21-30d control groups and in the TGF-b20-17d/
Decorin21-30d–treated groups, with (E) quantification of pixel intensities above the threshold from a defined region within the TM that was set in
Intact control eyes. The data demonstrate that in the TGF-b0-17d/Decorin21-30d–treated group there was increased levels of both MMPs and decreased
levels of TIMP2 in the TM tissues (***P < 0.001); Scale bar: 100 lm for (A) and 50 lm for (B–D).
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FIGURE 9. In vivo and in vitro RGC survival after Decorin treatment. The panels illustrate Brn3aþ/DAPIþ staining in the GCL of the (A) TGF-b10-17d/
PBS21-30d–treated group and (B) TGF-b20-17d/Decorin21-30d–treated group. The graphs show quantitation of RGC survival (C) in vivo in the TGF-b10-
17d/PBS21-30d–treated and the TGF-b20-17d/Decorin21-30d–treated groups and (D) in vitro after retinal cell culture with various concentrations of
Decorin. Retinal ganglion cell death was significantly reduced in the TGF-b20-17d/Decorin21-30d group compared with the TGF-b10-17d/PBS21-30d
group (***P < 0.001; Scale bar: 100 lm). However, there was no significant direct neuroprotective effect of Decorin on RGC in vitro.
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consequence of MMP-induced dissolution of TM fibrosis.
Currently, there is no precise explanation of why high IOP
causes RGC death, a multitude of factors may contribute,
including compromised retrograde axonal transport of target-
derived neurotrophic factors, activation of apoptosis and
mitochondrial dysfunction after biomechanical and ischemic
insults caused by compression of the optic nerve head as a
result of raised IOP.79
In conclusion, our observations suggest that IC Decorin
effectively reversed established TM fibrosis and normalized
IOP, thereby indirectly protecting RGC from progressive IOP-
related death. Thus, Decorin has the potential to be developed
into an effective therapy for patients with ocular hypertension
and forms of open-angle glaucoma associated with TM fibrosis.
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